All In Biotech

NDA 022334 · Novartis

Afinitor

Everolimus · Oral · Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Mar 30, 2009

Approved uses

16

Original approval plus efficacy supplements

Registered trials

881

126 Phase 3, 57 recruiting

FAERS reports

49,330

38,255 serious, 10,696 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 1, 2026.

AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 ) 1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole. 1.2 Neuroendocrine Tumors (NET) AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or...

Mechanism: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers and in tuberous sclerosis complex (TSC). Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis....

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • AFINITOR · EVEROLIMUS 7.5MG · TABLET, ORAL · Prescription · TE AB
  • AFINITOR · EVEROLIMUS 10MG · TABLET, ORAL · Prescription · TE AB
  • AFINITOR · EVEROLIMUS 2.5MG · TABLET, ORAL · Prescription · TE AB
  • AFINITOR · EVEROLIMUS 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Everolimus" as an intervention, any sponsor and status, largest first.

All 881 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death6,201
  • malignant neoplasm progression4,730
  • diarrhoea4,043
  • fatigue3,792
  • stomatitis3,131
  • nausea2,831
  • dyspnoea2,603
  • drug ineffective2,360
  • decreased appetite2,113
  • pyrexia2,107
  • vomiting2,091
  • rash1,985

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20065
200715
200834
2009188
2010928
20111,441
20122,329
20132,124
20142,289
20153,950
20164,796
20173,988
20184,749
20194,680
20204,217
20213,392
20222,678
20232,517
20242,108
20251,586
20261,313

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Afinitor (Everolimus)

2024 spending

$17.7M

Beneficiaries

151

905 claims

Per beneficiary

$117,391

$629.78 per unit

View as table
YearSpending
2020$302,356,560
2021$216,178,594
2022$100,030,446
2023$29,755,095
2024$17,726,015

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,823 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.